Drug R&D cost study
Tufts University Center for the Study of Drug Development research associate Joseph DiMasi, PhD, will be the lead author of a benchmark study on drug R&D costs being prepared by the center. An adjunct assistant professor in economics at Tufts, DiMasi has been working on the study for over two years. A story in "The Pink Sheet" (Jan. 1, p. 3) on a preview of the study given at a recent IoM seminar by Duke University's Henry Grabowski, PhD, another of the study's investigators, inadvertently omitted DiMasi's name. The study, which estimates that the average cost of bringing a new drug to market now exceeds $200 mil., is expected to be ready for publication in "a couple of months".
You may also be interested in...
The independent, family-controlled German group has signed a third R&D pact with Danish biotech Gubra to develop poly-agonist peptides for obesity.
Inovio Pharmaceuticals has reported promising initial data from its first Phase III study of its electrical current-driven DNA plasmid-based immunotherapy, VGX-3100, in virus-associated cervical dysplasia; it is heading a small group of companies evaluating novel therapies in the condition, which often advances to cancer.
In the month ahead, a key ANDA approval could come for Viatris, while additional competition to Gilead Sciences’ Truvada for PrEP is on the way in the US following Teva and Amneal’s launches.